Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrin alpha-1/beta-1 (ITGA1/ITGB1)
- Target
- ITGA1/ITGB1
- Molecular classification
- Receptor, Integrin, Cell adhesion molecule
01
Overview
Integrin alpha-1/beta-1 is a transmembrane heterodimeric receptor composed of alpha-1 (ITGA1) and beta-1 (ITGB1) subunits. It acts primarily as a receptor for collagens (notably type IV collagen) and laminin, mediating cell adhesion to the extracellular matrix. Through its cytoplasmic domains, it links to the actin cytoskeleton and participates in bidirectional signal transduction, influencing cell migration, proliferation, and tissue structure. Integrin alpha-1/beta-1 is essential for normal development, tissue repair, and pathologically is implicated in cancer progression, tissue fibrosis, and certain neuromuscular disorders. It is under investigation as a therapeutic target, especially in oncology and fibrotic diseases, though no highly selective approved drugs currently target this complex.
- Other names
- CD49a (alpha-1)CD29 (beta-1)Very Late Antigen-1 (VLA-1 for alpha-1/beta-1 specifically)Collagen receptorLaminin receptor
02
Mechanism of action
Inhibition or blocking of ligand binding (e.g., collagen/laminin) to prevent adhesion and migration. Modulation of integrin-mediated intracellular signaling pathways that control survival, proliferation, and differentiation.
03
Biological functions
Cell adhesionSignal transductionCell migrationProliferationTissue repairExtracellular matrix (ECM) interaction
04
Disease associations
Cancer (tumor progression, metastasis)InflammationFibrosisMuscular dystrophyNeurodegenerative disease (indirectly, via impact on ECM and cell interaction)
05
Safety considerations
Broad inhibition of beta-1 integrin can affect many normal tissues due to its ubiquitous expression, leading to potential off-target effects including impaired wound healing, immune dysfunction, and cardiovascular effects.Targeting integrin alpha-1/beta-1 specifically may mitigate some broad-spectrum side effects, but this is still largely investigational.
06
Interacting drugs
No widely approved drugs specifically target integrin alpha-1/beta-1.
3 more in the full profile.
07
Biomarkers
Elevated integrin alpha-1/beta-1 expression used as a marker for certain tumor types and tissue remodeling conditions.Beta-1 integrin (CD29) is sometimes used in flow cytometry panels as a biomarker of cell state/activation
Beyond the preview
Go deeper on Integrin alpha-1/beta-1 (ITGA1/ITGB1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Integrin alpha-1/beta-1 (ITGA1/ITGB1).